Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
microRNA 21 | 0.363 | 0.846 |
|
group | 0.090 | None | 1.000 | 9 | 0 | 2009 | 2017 | |||||||||
|
H3 histone pseudogene 10 | 0.350 | 0.846 |
|
group | 0.050 | None | 1.000 | 5 | 0 | 1994 | 2017 | |||||||||
|
TERT 5' regulatory region | 0.464 | 0.731 |
|
group | 0.040 | None | 1.000 | 4 | 0 | 2013 | 2019 | |||||||||
|
interferon beta 1 | 0.421 | 0.846 |
|
group | 0.040 | None | 1.000 | 4 | 0 | 1992 | 2013 | |||||||||
|
HOX transcript antisense RNA | 0.475 | 0.769 |
|
group | 0.030 | None | 1.000 | 3 | 0 | 2014 | 2018 | |||||||||
|
long intergenic non-protein coding RNA 1194 | 0.470 | 0.769 |
|
group | 0.030 | None | 1.000 | 3 | 0 | 1995 | 2008 | |||||||||
|
CXADR pseudogene 1 | 0.463 | 0.846 |
|
group | 0.030 | None | 1.000 | 3 | 0 | 2017 | 2018 | |||||||||
|
PPP1R2C family member C | 0.478 | 0.846 |
|
group | 0.030 | None | 1.000 | 3 | 0 | 2014 | 2019 | |||||||||
|
chromosome 20 open reading frame 181 | 0.479 | 0.885 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 1995 | 2002 | |||||||||
|
H3 clustered histone 9, pseudogene | 0.656 | 0.538 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 2001 | 2001 | |||||||||
|
P2RX5-TAX1BP3 readthrough (NMD candidate) | 0.588 | 0.769 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 2011 | 2017 | |||||||||
|
microRNA 10b | 0.509 | 0.808 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 2013 | 2017 | |||||||||
|
microRNA 137 | 0.513 | 0.846 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 2008 | 2017 | |||||||||
|
microRNA 155 | 0.384 | 0.885 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 2009 | 2013 | |||||||||
|
microRNA 34a | 0.421 | 0.846 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 2009 | 2010 | |||||||||
|
miR-17-92a-1 cluster host gene | 0.483 | 0.808 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 2009 | 2018 | |||||||||
|
microRNA 326 | 0.560 | 0.731 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 2009 | 2018 | |||||||||
|
platelet and endothelial cell adhesion molecule 1 | 0.426 | 0.846 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 2004 | 2010 | |||||||||
|
suppression of anchorage independence 1 | 0.560 | 0.615 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 1995 | 2007 | |||||||||
|
Alzheimer disease 5 | 0.769 | 0.231 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 2006 | 2007 | |||||||||
|
Myeloproliferative syndrome, transient (transient abnormal | 0.528 | 0.731 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 2014 | 2014 | |||||||||
|
RAB6C antisense RNA 1 | 0.839 | 0.154 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2018 | 2018 | |||||||||
|
CD24 molecule | 0.472 | 0.769 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2015 | 2015 | |||||||||
|
endogenous retrovirus group K member 20 | 0.533 | 0.692 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2014 | 2014 | |||||||||
|
competing endogenous lncRNA 3 for miR-645 | 0.531 | 0.808 |
|
group | 0.010 | None | < 0.001 | 1 | 0 | 2008 | 2008 |